- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02680782
A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers
A Phase 1 Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers
This study will evaluate the safety, tolerability and pharmacokinetics of X4P-001 administered as 200 mg twice daily compared with 400 mg once daily.
This study will also assess the pharmacodynamic effects of X4P-001 administered as 200 mg twice daily compared with 400 mg once daily on levels of circulating white blood cells (total and by cell type).
Studie Overzicht
Gedetailleerde beschrijving
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Florida
-
Daytona Beach, Florida, Verenigde Staten, 32117
- Covance Cru, Inc.
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Between 18 and 65 years of age, inclusive.
- Have signed the current approved informed consent form.
- For women of childbearing potential, (a) agree to use effective contraceptive methods from screening, through the study, and for at least 4 weeks after the last dose of study drug; and (b) have a negative pregnancy test (serum or urine) at screening and on Day -1 prior to each Dosing period.
- For men, agree both to (a) use effective contraceptive methods and (b) abstain from donating sperm, from admission to the in-residence unit prior to the first Dosing Period, through the study, and for at least 4 weeks after the last dose of study drug.
- Be willing and able to comply with this protocol.
Exclusion Criteria:
- Is an employee of the Phase 1 unit or an immediate family member of an employee.
- Has a BMI <18.0 or >30.0.
- Has a history of hypersensitivity or allergy to any drug compound, food or other substance assessed as significant by the Investigator.
- Has a history or presence of any medical condition capable of altering absorption, metabolism or elimination of drugs (history of routine cholecystectomy is permitted).
- Has alcohol intake exceeding 21 units per week for males or 14 units per week for females, where 1 unit = 12 oz (360 mL) beer, 5 oz (150 mL) wine, or 1.5 oz (45 mL) distilled spirits.
- Has within the past 12 months used illicit drugs.
- Has within the past 6 months been a smoker or used tobacco or nicotine replacement products.
- Is within 6 months post-partum or termination of a pregnancy.
- Has within the past 30 days or 5 half-lives, whichever is longer, participated in any other clinical trial involving an investigational treatment.
- Has within the past 30 days had an acute medical illness, including an active infection.
- Has within the past 30 days donated more than 500 mL of blood.
- Has within the past 30 days, or is scheduled to have while participating in the study, surgery requiring general anesthesia.
- Has within the past 30 days, or is scheduled to have while participating in the study, any immunizations.
- Has within the past 14 days been nursing.
- Has within the past 14 days donated plasma.
- Has within the past 14 days used any prescription or over the counter medications, unless deemed acceptable by the Investigator.
- Has positive urine or serum test for drugs of abuse or for cotinine.
Has positive serologic laboratory tests:
- Human immunodeficiency virus (HIV-1 or -2)
- Hepatitis C virus (HCV)
- Hepatitis B virus (HBV)
- Has confirmed abnormal safety laboratory tests representing CTCAE Grade 2 or higher. Subjects with Grade 1 abnormalities may be enrolled with the approval of the Investigator and the Sponsor.
- Has insufficient venous access to permit the scheduled blood sampling.
- Has any other medical or personal condition or finding that, in the opinion of the Investigator, may potentially compromise the safety or compliance of the subject, or may preclude the subject's successful completion of the clinical trial.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: X4P-001 QD
Subjects will receive study drug in two dosing periods.
In this arm subjects will receive drug once daily in the first period, followed by twice daily in the second dosing period.
|
100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD.
Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.
Andere namen:
|
Experimenteel: X4P-001 BID
Subjects will receive study drug in two dosing periods.
In this arm subjects will receive drug twice daily in the first period, followed by once daily in the second dosing period.
|
100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD.
Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Incidence of treatment emergent adverse events (safety and tolerability) in subjects administered X4P-001 200 mg twice daily compared with 400 mg once daily.
Tijdsspanne: Up to 14 to 21 days post-last dose
|
Safety assessments include ongoing monitoring of adverse events, ongoing monitoring of concomitant medications and regulatory scheduled vital signs, physical examinations and laboratory tests (hematology, clinical chemistry, urinalysis and coagulation).
|
Up to 14 to 21 days post-last dose
|
Maximum Plasma Concentration (Cmax) of X4P-001 administered as 200 mg twice daily compared with 400 mg once daily.
Tijdsspanne: Up to 48 hours post-dose
|
Cmax data will be collected to determine the pharmacokinetics of X4P-001 administered as 200 mg twice daily and 400 mg once daily.
|
Up to 48 hours post-dose
|
Area under the curve (AUC) of X4P-001 administered as 200 mg twice daily compared with 400 mg once daily.
Tijdsspanne: Up to 48 hours post-dose
|
AUC data will be collected to determine the pharmacokinetics of X4P-001 administered as 200 mg twice daily and 400 mg once daily.
|
Up to 48 hours post-dose
|
Minimum Plasma Concentration (Cmin) of X4P-001 administered as 200 mg twice daily compared with 400 mg once daily.
Tijdsspanne: Up to 48 hours post-dose
|
Amin data will be collected to determine the pharmacokinetics of X4P-001 administered as 200 mg twice daily and 400 mg once daily.
|
Up to 48 hours post-dose
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
To assess the pharmacodynamic effects of X4P-001 administered as 200 mg twice daily compared with 400 mg once daily on levels of circulating white blood cells (total and by cell type).
Tijdsspanne: Up to 48 hours post-dose
|
Whole blood samples will be obtained for PD studies concurrently with the PK samples.
PD will be assessed via complete blood counts (CBC) with differential.
|
Up to 48 hours post-dose
|
To assess the pharmacodynamic effects of X4P-001 administered as 200 mg twice daily compared with 400 mg once daily on levels of circulating mononuclear cell phenotypes by cell surface markers.
Tijdsspanne: Up to 48 hours post-dose
|
Whole blood samples will be obtained for PD studies concurrently with the PK samples.
PD will be assessed via complete blood counts (CBC) with differential.
|
Up to 48 hours post-dose
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Lu Gan, MD, PhD, X4 Pharmaceuticals, Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- X4P-001-REGA
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Gezond
-
University of LeicesterNational Institute for Health Research, United KingdomVoltooidPatiënten met hartfalen en behouden ejectiefractie - HFpEF | Patiënten met hartfalen met verminderde ejectiefractie - HFrEF | Healthy Controls Group - Leeftijd en geslacht afgestemd
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesBeëindigdZiekte van Parkinson | Healthy Controls Group - Leeftijd en geslacht afgestemdFrankrijk
Klinische onderzoeken op X4P-001
-
X4 PharmaceuticalsActief, niet wervend
-
X4 PharmaceuticalsVoltooidMacroglobulinemie van WaldenströmVerenigde Staten, Griekenland
-
X4 PharmaceuticalsNog niet aan het werven
-
X4 PharmaceuticalsVoltooidWHIM-syndroomAustralië, Verenigde Staten
-
Abbisko Therapeutics Co, LtdAanmelden op uitnodigingDrievoudige negatieve borstkankerChina
-
X4 PharmaceuticalsActief, niet wervendWHIM-syndroomVerenigde Staten, Denemarken, Australië, Oostenrijk, Frankrijk, Hongarije, Israël, Italië, Korea, republiek van, Nederland, Russische Federatie, Spanje, Kalkoen
-
X4 PharmaceuticalsVoltooidMelanomaVerenigde Staten
-
X4 PharmaceuticalsVoltooidHeldercellig niercelcarcinoomVerenigde Staten, Korea, republiek van
-
X4 PharmaceuticalsBeëindigdHeldercellig niercelcarcinoomVerenigde Staten
-
Toll Biotech Co. Ltd. (Beijing)Werving